Operator
Greetings, and welcome to the Collegium Pharmaceutical First Quarter 2021 Earnings Call. [Operator Instructions] As a reminder, this conference is being recorded.
It is now my pleasure to introduce your host, Alex Dasalla. Please go ahead.
Alex Dasalla
Head of Investor Relations
Welcome to Collegium Pharmaceuticals first quarter 2021 earnings conference call. This is Alex Dasalla, Head of Investor Relations for Collegium. I am joined today by Joe Ciaffoni, our Chief Executive Officer; Paul Brannelly, our Chief Financial Officer; and Scott Dreyer, our Chief Commercial Officer.
Before we begin today s call, we want to remind participants that none of the information presented today is intended to be promotional and that any forward-looking statements made today are made pursuant to the Safe Harbor provision of the Private Securities Litigation Reform Act of 1995. You are cautioned that such forward-looking statements involve risks and uncertainties, including and with
Operator
3Greetings. Welcome to the Amphastar Pharmaceuticals Inc. First Quarter Earnings Call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. [Operator Instructions].
All statements on this conference call that are not historical are forward-looking statements, including, among other things, statements relating to our expectations regarding future financial performance, backlog, sales and marketing of our products, market size and growth, product development, the timing of FDA filings or approvals, including the DMF of AMP, the timing of product launches, acquisitions and other matters related to our pipeline of product candidates, our share buyback program and other future events, such as the impact of the COVID-19 pandemic and related responses of business and governments to the pandemic on our operations and personnel, and on commercial activity and demand across our business operations, and results o
Markets
Needham analyst Serge Belanger maintained a Buy rating on Aerie Pharma (AERI – Research Report) today and set a price target of $26.00. The company’s shares closed last Tuesday at $17.66.
According to TipRanks.com, Belanger is a 4-star analyst with an average return of 8.8% and a 49.5% success rate. Belanger covers the Healthcare sector, focusing on stocks such as Amphastar Pharmaceuticals, KalVista Pharmaceuticals, and Collegium Pharmaceutical.
Aerie Pharma has an analyst consensus of Strong Buy, with a price target consensus of $27.25, implying a 47.6% upside from current levels. In a report issued on April 15, Oppenheimer also maintained a Buy rating on the stock with a $26.00 price target.